Revvity Announces Financial Results for the Third Quarter of 2026
November 3, 2026 Revvity Announces Financial Results for the Third Quarter of 2026 • Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma revenue growth; 7% pro forma organic revenue growth
; GAAP pro forma EPS from continuing operations of $0.60; pro forma adjusted EPS from continuing operations of $1.37
Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended October 4, 2026.
The Company reported GAAP earnings per share from continuing operations of $0.56, as compared to $0.41 in the same period a year ago. Revenue for the quarter was $729 million, as compared to $699 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $95 million, as compared to $82 million for the same period a year ago. GAAP operating profit margin from continuing operations was 13.1% as a percentage of revenue, as compared to 11.7% in the same period a year ago.
Adjusted earnings per share from continuing operations for the quarter was $1.38, as compared to $1.18 in the same period a year ago. Adjusted operating income was $209 million, as compared to $182 million for the same period a year ago. Adjusted operating profit margin was 28.7% as a percentage of revenue, as compared to 26.1% in the same period a year ago.
As a reminder, the Company entered into a definitive agreement to divest its Immunodiagnostics business in China ( “ China IDX ” ), which represented approximately 6% of the Company’s total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals. The Company is providing third quarter 2026 financial results on a reported and pro forma basis; forward- looking guidance is provided on a pro forma basis only and excludes China IDX.
Pro forma earnings per share from continuing operations for the quarter was $0.60, as compared to $0.40 in the same period a year ago. Pro forma revenue for the quarter was $710 million, as compared to $660 million in the same period a year ago. Pro forma operating income was $102 million, as compared to $77 million in the same period a year ago. Pro forma operating profit margin was 14.3% as a percentage of pro forma revenue, as compared to 11.7% in the same period a year ago.
On a pro forma adjusted basis, earnings per share for the quarter was $1.37, as compared to $1.13 in the same period a year ago. Pro forma adjusted operating income was $209 million, as compared to $172 million for the same period a year ago. Pro forma adjusted operating profit margin was 29.4% as a percentage of pro forma revenue, as compared to 26.0% in the same period a year ago.
Adjustments for the Company’s non-GAAP financial measures have been noted in the attached reconciliations.
“Our exceptional third quarter performance demonstrates the momentum building across Revvity, as broad-based growth and strong execution drove results meaningfully ahead of our expectations,” said Prahlad Singh, president and chief executive officer of Revvity. “With end market conditions continuing to improve, a strong pipeline of innovation, and the benefits of our transformation increasingly evident in our results, Revvity is extremely well positioned to capitalize on the opportunities ahead.”
• Third quarter 2026 revenue was $380 million, as compared to $343 million in the same period a year ago. Pro forma revenue increased 11% and pro forma organic revenue increased 9% as compar ed to the same period a year ago.
• Third quarter 2026 adjusted operating income was $119 million, as compared to $101 million in the same period a year ago. Adjusted operating profit margin was 31.5% as a percentage of revenue, as compared to 29.5% in the same period a year ago.
• Third quarter 2026 revenue was $349 million, as compared to $356 million in the same period a year ago. Pro forma revenue increased 4% and pro forma organic revenue increased 5% as compared to the same period a year ago.
• Third quarter 2026 adjusted operating income was $104 million, as compared to $89 million in the same period a year ago. Adjusted operating profit margin was 29.9% as a percentage of revenue, as compared to 25.1% in the same period a year ago.
For the full year 2026, on a pro forma basis, the Company forecasts total revenue of approximately $2.86 billion, pro forma organic revenue growth of approximately 5%, and pro forma adjusted earnings per share of $5.40-$5.45.
Guidance for the full year 2026 for pro forma organic revenue growth and pro forma adjusted EPS is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.
The Company will discuss its third quarter 2026 results and its outlook for business trends during a webcast on November 3, 2026, at 7:30 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company’s website, ir.revvity.com.
Revvity will be hosting its 2026 Investor Day on Friday, November 13 beginning at 9:00 a.m. ET. Registration details can be found at ir.revvity.com. Presentations from members of Revvity’s senior management team will provide updates on the Company’s key business initiatives, operational achievements and financial outlook.
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.
This press release contains “ forward-looking ” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as “ believes ” , “ intends ” , “ anticipates ” , “ plans ” , “ expects ” , “ estimates ” , “ projects ” , “ forecasts ” , “ will ” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments, including as the result of recently implemented and recently threatened tariff increases; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third- party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) uncertainties related to the development and use of AI in our product offerings and internal operations; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) our failure to comply with data privacy and information security laws and regulations; (18) regulatory changes; (19) our failure to comply with healthcare industry regulations; (20) economic, political and other risks associated with foreign operations; (21) our ability to obtain future financing; (22) restrictions in our credit agreements; (23) significant fluctuations in our stock price; (24) reduction or elimination of dividends on our common stock; and (25) other factors which we describe under the caption “ Risk Factors ” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
Continuing Operations Three Months Ended October 4, 2026 ─────────────────────────────────────────────────────────────────────────── Pro forma organic revenue growth: Pro forma revenue growth from continuing 7% operations Less: effect of foreign exchange rates -1% Less: effect of acquisitions including purchase accounting adjustments and impact of divested 1% businesses Pro forma organic revenue growth from continuing 7% operations Life Sciences Three Months Ended October 4, 2026 Pro forma organic revenue growth: Pro forma revenue growth from continuing 11% operations Less: effect of foreign exchange rates 0% Less: effect of acquisitions including purchase accounting adjustments and impact of divested 2% businesses Pro forma organic revenue growth from continuing 9% operations Diagnostics Three Months Ended October 4, 2026 Pro forma organic revenue growth: Pro forma revenue growth from continuing 4% operations Less: effect of foreign exchange rates -1% Less: effect of acquisitions including purchase accounting adjustments and impact of divested 0% businesses Pro forma organic revenue growth from continuing 5% operations (1) amounts may not sum due to rounding
Continuing Operations Nine Months Ended October 4, 2026 ─────────────────────────────────────────────────────────────────────────── Pro forma organic revenue growth: Pro forma revenue growth from continuing 7% operations Less: effect of foreign exchange rates 1% Less: effect of acquisitions including purchase accounting adjustments and impact of divested 1% businesses Pro forma organic revenue growth from continuing 5% operations Life Sciences Nine Months Ended October 4, 2026 Pro forma organic revenue growth: Pro forma revenue growth from continuing 5% operations Less: effect of foreign exchange rates 1% Less: effect of acquisitions including purchase accounting adjustments and impact of divested 1% businesses Pro forma organic revenue growth from continuing 3% operations Diagnostics Nine Months Ended October 4, 2026 Pro forma organic revenue growth: Pro forma revenue growth from continuing 9% operations Less: effect of foreign exchange rates 1% Less: effect of acquisitions including purchase accounting adjustments and impact of divested 0% businesses Pro forma organic revenue growth from continuing 8% operations (1) amounts may not sum due to rounding
We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.
We use the term “organic revenue” to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions, divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “organic revenue growth” or “organic growth” to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year.
We use the term “adjusted gross margin” to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions and asset impairments. We use the related term “adjusted gross margin percentage” to refer to adjusted gross margin as a percentage of revenue.
We use the term “adjusted SG&A expense” to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, asset impairments, significant environmental charges, and restructuring and other charges. We use the related term “adjusted SG&A percentage” to refer to adjusted SG&A expense as a percentage of revenue.
We use the term “adjusted R&D expense” to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term “adjusted R&D percentage” to refer to adjusted R&D expense as a percentage of revenue.
We use the term “adjusted net interest and other expense” to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in foreign exchange and interest associated with acquisitions and divestitures, changes in the value of investments and debt extinguishment costs.
We use the term “adjusted operating income” to refer to GAAP operating income, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms “adjusted operating profit percentage,” “adjusted operating profit margin,” and “adjusted operating margin” to refer to adjusted operating income as a percentage of revenue.
We use the term “free cash flow” to refer to net cash provided by (used in) operating activities of continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”).
We use the term “adjusted net income” to refer to GAAP income from continuing operations, excluding amortization of intangible assets, debt extinguishment costs, purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, significant environmental charges, changes in the value of investments, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.
We use the term “adjusted earnings per share from continuing operations,” “adjusted earnings per share,” “adjusted EPS,” or “adjusted EPS from continuing operations” to refer to GAAP earnings per share from continuing operations, excluding amortization of intangible assets, debt extinguishment costs, purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, significant environmental charges, changes in the value of investments, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.
We use the term “pro forma organic revenue” to refer to organic revenue excluding revenue from probable dispositions. We use the related term “pro forma organic revenue growth”, “pro forma organic revenue growth from continuing operations” or “pro forma organic growth” to refer to the measure of comparing current period pro forma organic revenue with the corresponding period of the prior year.
We use the term “pro forma adjusted gross margin” to refer to adjusted gross margin, excluding gross margin from probable dispositions. We use the related term “pro forma adjusted gross margin percentage” to refer to pro forma adjusted gross margin as a percentage of pro forma revenue.
We use the term “pro forma adjusted SG&A expense” to refer to adjusted SG&A expense, excluding SG&A expense from probable dispositions and gains(losses) on sale of probable dispositions. We use the related term “pro forma adjusted SG&A percentage” to refer to pro forma adjusted SG&A expense as a percentage of pro forma revenue.
We use the term “pro forma adjusted R&D expense” to refer to adjusted R&D expense, excluding R&D expense from probable dispositions. We use the related term “pro forma adjusted R&D percentage” to refer to pro forma adjusted R&D expense as a percentage of pro forma revenue.
We use the term “pro forma adjusted net interest and other expense” to refer to adjusted net interest and other expense, excluding net interest and expense from probable dispositions.
We use the term “pro forma adjusted operating income” to refer to adjusted operating income, excluding operating income from probable dispositions. We use the related terms “pro forma adjusted operating profit percentage,” “pro forma adjusted operating profit margin,” and “pro forma adjusted operating margin” to refer to pro forma adjusted operating income as a percentage of pro forma revenue.
We use the term “pro forma adjusted earnings per share from continuing operations,” “pro forma adjusted earnings per share,” “pro forma adjusted EPS,” or “pro forma adjusted EPS from continuing operations” to refer to adjusted earnings per share from continuing operations, excluding net income from probable dispositions and gains (losses) on sale of probable dispositions.
Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:
• Amortization of intangible assets —purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
• Debt extinguishment costs —we incur costs and income related to the extinguishment of debt, including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
• Purchase accounting adjustments —accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets, deferred revenue and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.
• Acquisition and divestiture-related expenses —we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest, foreign exchange gains and losses, integration expenses, rebranding expenses, and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
• Transformation costs —transformation costs consist of external professional service costs related to transformation initiatives focused on business processes modernization, automation, and implementation of global systems to support the new Revvity Business Model. T hese costs are determined to be noncapitalizable in accordance with accounting standards. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.
• Asset impairments —we incur expenses related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
• Restructuring and other charges —restructuring and other charges consist of employee severance, other exit costs, abandonments or associated asset write- downs, cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.
• Adjustments for mark-to-market accounting on post-retirement benefits —we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.
• Significant litigation matters and settlements —we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
• Significant environmental charges —we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
• Disposition of businesses and assets, net —we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
• Impact of foreign currency changes on the current period —we exclude the impact of foreign currency associated with acquisitions and divestitures from these measures by using the prior period’s foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.
• Impact of significant tax events —we exclude the impact of significant tax events. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded.
• Change in fair value of investments —we exclude the impact of changes in the value of investments. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported. # # # The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board’s Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, transformation costs, loss from probable dispositions, significant litigation matters and settlements, significant environmental charges, changes in the fair value of investments, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, and restructuring and other charges is calculated based on operational results and a blended jurisdictional tax rate, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on a blended jurisdictional tax rate currently in effect to determine our tax provision.
The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.
Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.
Full text with the tables
FOR IMMEDIATE RELEASE
November 3, 2026
Revvity Announces Financial Results for the Third Quarter of 2026
• Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma
revenue growth; 7% pro forma organic revenue growth
•
GAAP EPS from continuing operations of
$0.56
;
adjusted EPS from continuing operations of $1.38
; GAAP pro forma EPS from continuing operations of $0.60; pro forma adjusted EPS
from continuing operations of $1.37
•
Raises full year guidance
•
Investor Day to be held November 13, 2026
WALTHAM, Mass. --
Revvity, Inc. (NYSE: RVTY), today reported financial results for the third
quarter ended October 4, 2026.
The Company reported GAAP earnings per share from continuing operations of
$0.56, as compared to $0.41 in the same period a year ago. Revenue for the
quarter was $729 million, as compared to $699 million in the same period a year
ago. GAAP operating income from continuing operations for the quarter was $95
million, as compared to $82 million for the same period a year ago. GAAP
operating profit margin from continuing operations was 13.1% as a percentage of
revenue, as compared to 11.7% in the same period a year ago.
Adjusted earnings per share from continuing operations for the quarter was
$1.38, as compared to $1.18 in the same period a year ago. Adjusted operating
income was $209 million, as compared to $182 million for the same period a year
ago. Adjusted operating profit margin was 28.7% as a percentage of revenue, as
compared to 26.1% in the same period a year ago.
As a reminder, the Company entered into a definitive agreement to divest its
Immunodiagnostics business in China ( “ China IDX ” ), which represented
approximately 6% of the Company’s total revenue in fiscal year 2025. The
transaction is expected to close by the end of 2027, subject to customary
closing conditions and regulatory approvals. The Company is providing third
quarter 2026 financial results on a reported and pro forma basis; forward-
looking guidance is provided on a pro forma basis only and excludes China IDX.
Pro forma earnings per share from continuing operations for the quarter was
$0.60, as compared to $0.40 in the same period a year ago. Pro forma revenue for
the quarter was $710 million, as compared to $660 million in the same period a
year ago. Pro forma operating income was $102 million, as compared to $77
million in the same period a year ago. Pro forma operating profit margin was
14.3% as a percentage of pro forma revenue, as compared to 11.7% in the same
period a year ago.
On a pro forma adjusted basis, earnings per share for the quarter was $1.37, as
compared to $1.13 in the same period a year ago. Pro forma adjusted operating
income was $209 million, as compared to $172 million for the same period a year
ago. Pro forma adjusted operating profit margin was 29.4% as a percentage of pro
forma revenue, as compared to 26.0% in the same period a year ago.
Adjustments for the Company’s non-GAAP financial measures have been noted in the
attached reconciliations.
“Our exceptional third quarter performance demonstrates the momentum building
across Revvity, as broad-based growth and strong execution drove results
meaningfully ahead of our expectations,” said Prahlad Singh, president and chief
executive officer of Revvity. “With end market conditions continuing to improve,
a strong pipeline of innovation, and the benefits of our transformation
increasingly evident in our results, Revvity is extremely well positioned to
capitalize on the opportunities ahead.”
Financial Overview by Reporting Segment
Life Sciences
• Third quarter 2026 revenue was $380 million, as compared to $343 million in
the same period a year ago. Pro forma revenue increased 11% and pro forma
organic revenue increased 9% as compar ed to the same period a year ago.
• Third quarter 2026 adjusted operating income was $119 million, as compared to
$101 million in the same period a year ago. Adjusted operating profit margin was
31.5% as a percentage of revenue, as compared to 29.5% in the same period a year
ago.
Diagnostics
• Third quarter 2026 revenue was $349 million, as compared to $356 million in
the same period a year ago. Pro forma revenue increased 4% and pro forma organic
revenue increased 5% as compared to the same period a year ago.
• Third quarter 2026 adjusted operating income was $104 million, as compared to
$89 million in the same period a year ago. Adjusted operating profit margin was
29.9% as a percentage of revenue, as compared to 25.1% in the same period a year
ago.
Full Year 2026 Guidance
For the full year 2026, on a pro forma basis, the Company forecasts total
revenue of approximately $2.86 billion, pro forma organic revenue growth of
approximately 5%, and pro forma adjusted earnings per share of $5.40-$5.45.
Guidance for the full year 2026 for pro forma organic revenue growth and pro
forma adjusted EPS is provided on a non-GAAP basis and cannot be reconciled to
the closest GAAP measures without unreasonable effort due to the
unpredictability of the amounts and timing of events affecting the items the
Company excludes from these non-GAAP measures. The timing and amounts of such
events and items could be material to the Company’s results prepared in
accordance with GAAP.
Webcast Information
The Company will discuss its third quarter 2026 results and its outlook for
business trends during a webcast on November 3, 2026, at 7:30 a.m. Eastern Time.
A live audio webcast and presentation will be available on the Investors section
of the Company’s website, ir.revvity.com.
Investor Day
Revvity will be hosting its 2026 Investor Day on Friday, November 13 beginning
at 9:00 a.m. ET. Registration details can be found at ir.revvity.com.
Presentations from members of Revvity’s senior management team will provide
updates on the Company’s key business initiatives, operational achievements and
financial outlook.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted
accounting principles (GAAP), this earnings announcement also contains non-GAAP
financial measures. The reasons that we use these measures, a reconciliation of
these measures to the most directly comparable GAAP measures, and other
information relating to these measures are included below following our GAAP
financial statements.
Factors Affecting Future Performance
This press release contains “ forward-looking ” statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including, but not limited
to, statements relating to estimates and projections of future earnings per
share, cash flow and revenue growth and other financial results, developments
relating to our customers and end-markets, and plans concerning business
development opportunities, acquisitions and divestitures. Words such as “
believes ” , “ intends ” , “ anticipates ” , “ plans ” , “ expects ” , “
estimates ” , “ projects ” , “ forecasts ” , “ will ” and similar expressions,
and references to guidance, are intended to identify forward-looking statements.
Such statements are based on management's current assumptions and expectations
and no assurances can be given that our assumptions or expectations will prove
to be correct. A number of important risk factors could cause actual results to
differ materially from the results described, implied or projected in any
forward-looking statements. These factors include, without limitation: (1)
markets into which we sell our products declining or not growing as anticipated;
(2) fluctuations in the global economic and political environments, including as
the result of recently implemented and recently threatened tariff increases; (3)
our failure to introduce new products in a timely manner; (4) our ability to
execute acquisitions and divestitures, license technologies, or to successfully
integrate acquired businesses or licensed technologies into our existing
businesses or to make them profitable; (5) our ability to compete effectively;
(6) fluctuation in our quarterly operating results and our ability to adjust our
operations to address unexpected changes; (7) significant disruption in third-
party package delivery and import/export services or significant increases in
prices for those services; (8) disruptions in the supply of raw materials and
supplies; (9) our ability to retain key personnel; (10) significant disruption
in our information technology systems, or cybercrime; (11) uncertainties related
to the development and use of AI in our product offerings and internal
operations; (12) our ability to realize the full value of our intangible assets;
(13) our failure to adequately protect our intellectual property; (14) the loss
of any of our licenses or licensed rights; (15) the manufacture and sale of
products exposing us to product liability claims; (16) our failure to maintain
compliance with applicable government regulations; (17) our failure to comply
with data privacy and information security laws and regulations; (18) regulatory
changes; (19) our failure to comply with healthcare industry regulations; (20)
economic, political and other risks associated with foreign operations; (21) our
ability to obtain future financing; (22) restrictions in our credit agreements;
(23) significant fluctuations in our stock price; (24) reduction or elimination
of dividends on our common stock; and (25) other factors which we describe under
the caption “ Risk Factors ” in our most recent quarterly report on Form 10-Q
and in our other filings with the Securities and Exchange Commission. We
disclaim any intention or obligation to update any forward-looking statements as
a result of developments occurring after the date of this press release.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to
action. Revvity provides health science solutions, technologies, expertise and
services that deliver complete workflows from discovery to development, and
diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare,
with specialized focus areas in translational multi-omics technologies,
biomarker identification, imaging, prediction, screening, detection and
diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity
serves customers across pharmaceutical and biotech, diagnostic labs, academia
and governments. It is part of the S&P 500 index and has customers in more than
160 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and
Instagram.
Revvity, Inc. and Subsidiaries
CONDENSED CONSOLIDATED INCOME STATEMENTS
Three Three
Months Months
Ended Ended
Octob… Septe…
4, 28,
2026 2025
──────────────────────────────────────────────────────────────────────────────
(In
thou…
exce… As Pro As Pro
per Repor… Forma Repor… Forma
share
data)
Reve… $ 728,8… $ 709,6… $ 698,9… $ 660,4…
Cost
of 310,3… 301,2… 324,3… 302,0…
reve…
Sell…
gene…
and 275,3… 259,4… 241,9… 230,0…
admi…
expe…
Rese…
and 48,108 47,302 50,797 50,797
deve…
expe…
Oper…
inco…
from 95,141 101,6… 81,896 77,464
cont…
oper…
Inte… -3,545 -3,533 -6,925 -6,909
inco…
Inte… 20,813 20,813 22,771 22,771
expe…
Chan…
in
fair -1,627 -1,627 4,602 4,602
value
of
inve…
Other
expe… 1,817 3,722 5,763 5,088
net
Inco…
from
cont…
oper… 77,683 82,244 55,685 51,912
befo…
inco…
taxes
Prov…
for 15,062 14,868 8,464 6,574
inco…
taxes
Inco…
from 62,621 67,376 47,221 45,338
cont…
oper…
Loss
from -322 -322 -569 -569
disc…
oper…
Net $ 62,299 $ 67,054 $ 46,652 $ 44,769
inco…
Dilu…
earn…
per
shar…
Inco…
from $ 0.56 $ 0.60 $ 0.41 $ 0.40
cont…
oper…
Loss
from -0.00 -0.00 -0.01 -0.01
disc…
oper…
Net $ 0.56 $ 0.60 $ 0.40 $ 0.39
inco…
Weig…
aver…
dilu…
shar… 111,8… 111,8… 115,4… 115,4…
of
comm…
stock
outs…
ABOVE
PREP…
IN
ACCO…
WITH
GAAP
Add…
sup… Three Three
inf… Mont… Mont…
(per Ended Ended
sha… Octo… Sept…
con… 4, 28,
ope… 2026 2025
──────────────────────────────────────────────────────────────────────────────
As Pro As Pro
Repo… Forma Repor… Forma
GAAP
EPS
from $ 0.56 $ 0.60 $ 0.41 $ 0.40
con…
ope…
Amo…
of 0.76 0.70 0.73 0.68
int…
ass…
Pur…
acc… 0.00 0.00 0.00 0.00
adj…
Acq…
and 0.00 0.00 0.00 0.00
div…
cos…
Tra… 0.01 0.01 0.04 0.04
cos…
Cha…
in
fair -0.01 -0.01 0.04 0.04
val…
of
inv…
Sig…
lit…
mat… — — 0.01 0.01
and
set…
Res…
and 0.25 0.25 0.09 0.08
oth…
Tax
on -0.18 -0.17 -0.17 -0.16
abo…
ite…
Sig…
tax — — 0.03 0.03
ite…
Adj…
EPS
from $ 1.38 $ 1.37 $ 1.18 $ 1.13
con…
ope…
(1)
amo…
may
not
sum
due
to
rou…
Revvity, Inc. and Subsidiaries
CONDENSED CONSOLIDATED INCOME STATEMENTS
Nine Nine
Months Months
Ended Ended
Octob… Septe…
4, 28,
2026 2025
──────────────────────────────────────────────────────────────────────────────
(In
thou…
exce… As Pro As Pro
per Repor… Forma Repor… Forma
share
data)
Reve… $ 2,169… $ 2,107… $ 2,083… $ 1,969…
Cost
of 946,6… 913,2… 941,2… 880,2…
reve…
Sell…
gene…
and 807,7… 764,9… 740,1… 749,8…
admi…
expe…
Rese…
and 154,9… 153,9… 157,6… 157,6…
deve…
expe…
Oper…
inco…
from 260,3… 275,3… 244,8… 181,9…
cont…
oper…
Inte… -15,1… -15,0… -25,3… -25,3…
inco…
Inte… 68,521 68,521 68,672 68,672
expe…
Chan…
in
fair 7,828 7,828 3,484 3,484
value
of
inve…
Other
expe… 7,896 10,289 21,364 19,384
net
Inco…
from
cont…
oper… 191,2… 203,8… 176,7… 115,7…
befo…
inco…
taxes
Prov…
for 34,211 32,682 32,605 30,238
inco…
taxes
Inco…
from 156,9… 171,1… 144,1… 85,462
cont…
oper…
Loss
from -2,158 -2,158 -1,275 -1,275
disc…
oper…
Net $ 154,8… $ 168,9… $ 142,8… $ 84,187
inco…
Dilu…
earn…
per
shar…
Inco…
from $ 1.40 $ 1.53 $ 1.22 $ 0.73
cont…
oper…
Loss
from -0.02 -0.02 -0.01 -0.01
disc…
oper…
Net $ 1.38 $ 1.51 $ 1.21 $ 0.72
inco…
Weig…
aver…
dilu…
shar… 111,7… 111,7… 117,7… 117,7…
of
comm…
stock
outs…
ABOVE
PREP…
IN
ACCO…
WITH
GAAP
Ad…
su… Nine Nine
in… Mon… Mon…
(p… End… End…
sh… Oct… Sep…
co… 4, 28,
op… 2026 2025
──────────────────────────────────────────────────────────────────────────────
As Pro As Pro
Rep… For… Rep… For…
GA…
EPS
fr… $ 1.40 $ 1.53 $ 1.22 $ 0.…
co…
op…
Am…
of 2.28 2.10 2.14 2.…
in…
as…
Pu…
ac… 0.02 0.02 0.02 0.…
ad…
Ac…
and 0.01 0.01 0.02 0.…
di…
co…
Tr… 0.01 0.01 0.05 0.…
co…
Ch…
in
fa… 0.07 0.07 0.03 0.…
va…
of
in…
Lo…
fr… — — — 0.…
pr…
di…
Si…
li…
ma… 0.00 0.00 0.11 0.…
and
se…
Si…
en… — — -0.… -0…
ma…
Di…
of
bu… -0.… -0.… — —
and
as…
net
Ma…
to
ma… -0.… -0.… 0.04 0.…
on
po…
be…
Re…
and 0.67 0.65 0.21 0.…
ot…
Tax
on -0.… -0.… -0.… -0…
ab…
it…
Si…
tax — — 0.03 0.…
it…
Ad…
EPS
fr… $ 3.85 $ 3.82 $ 3.37 $ 3.…
co…
op…
(1)
am…
may
not
sum
due
to
ro…
Revvity, Inc. and Subsidiaries
REVENUE AND OPERATING INCOME (LOSS)
Thr… Thr…
Mon… Mon…
End… End…
Oct… Sep…
4, 28,
2026 2025
──────────────────────────────────────────────────────────────────────────────
(In
tho… As Pro As Pro
exc… Repo… Forma Repo… Forma
per…
Rev…
and
adj…
ope…
inc…
Rev… $ 728… $ 709… $ 698… $ 660…
Ope…
inc…
from $ 95,… $ 101… $ 81,… $ 77,…
con…
ope…
OP% 13.1 % 14.3 % 11.7 % 11.7 %
Amo…
of 84,… 78,… 84,… 78,…
int…
ass…
Pur…
acc… 300 300 348 348
adj…
Acq…
and 70 70 284 284
div…
cos…
Tra… 612 612 5,1… 5,1…
cos…
Sig…
lit…
mat… 150 150 785 785
and
set…
Res…
and 28,… 27,… 9,9… 9,3…
oth…
Adj…
ope… $ 209… $ 208… $ 182… $ 171…
inc…
OP% 28.7 % 29.4 % 26.1 % 26.0 %
Three
Mont…
Ended
Octo… Sept…
4, 28,
2026 2025
-In
thou…
exce…
perc…
Seg…
rev…
Life $ 379… $ 342…
Sci…
Dia… 349… 356…
Seg… 728… 698…
rev…
Seg…
ope…
inc…
Life $ 119… $ 101…
Sci…
31.5 % 29.5 %
Dia… 104… 89,…
29.9 % 25.1 %
Seg…
ope… 223… 190…
inc…
Cor… -14… -8,…
Adj…
ope… 209… 182…
inc…
Amo…
of -84… -84…
int…
ass…
Pur…
acc… -300 -348
adj…
Acq…
and -70 -284
div…
cos…
Tra… -612 -5,…
cos…
Sig…
lit…
mat… -150 -785
and
set…
Res…
and -28… -9,…
oth…
Rep…
ope…
inc… $ 95,… $ 81,…
from
con…
ope…
REV…
AND
REP…
OPE…
INC…
(LO…
PRE…
IN
ACC…
WITH
GAAP
Revvity, Inc. and Subsidiaries
REVENUE AND OPERATING INCOME (LOSS)
Nine Nine
Mon… Mon…
End… End…
Oct… Sep…
4, 28,
2026 2025
──────────────────────────────────────────────────────────────────────────────
(In
tho… As Pro As Pro
exc… Repo… Forma Repo… Forma
per…
Rev…
and
adj…
ope…
inc…
Rev… $ 2,1… $ 2,1… $ 2,0… $ 1,9…
Ope…
inc…
from 260… 275… 244… 181…
con…
ope…
OP% 12.0 % 13.1 % 11.8 % 9.2 %
Amo…
of 254… 235… 252… 235…
int…
ass…
Pur…
acc… 2,3… 2,3… 2,3… 2,3…
adj…
Acq…
and 456 394 2,9… 2,9…
div…
cos…
Dis…
of
bus… -5,… -5,… — —
and
ass…
net
Tra… 671 670 6,2… 6,2…
cos…
Loss
from — — — 46,…
pro…
dis…
Sig…
lit…
mat… 298 298 12,… 12,…
and
set…
Sig…
env… — — -1,… -1,…
mat…
Res…
and 74,… 73,… 24,… 23,…
oth…
Adj…
ope… $ 588… $ 582… $ 544… $ 511…
inc…
OP% 27.1 % 27.6 % 26.1 % 26.0 %
Nine
Mont…
Ended
Octo… Sept…
4, 28,
2026 2025
-In
thou…
exce…
perc…
Seg…
rev…
Life $ 1,1… $ 1,0…
Sci…
Dia… 1,0… 1,0…
Seg… 2,1… 2,0…
rev…
Seg…
ope…
inc…
Life $ 334… $ 322…
Sci…
30.4 % 30.7 %
Dia… 293… 252…
27.4 % 24.4 %
Seg…
ope… 628… 575…
inc…
Cor… -40… -30…
Adj…
ope… 588… 544…
inc…
Amo…
of -25… -25…
int…
ass…
Pur…
acc… -2,… -2,…
adj…
Acq…
and -456 -2,…
div…
cos…
Dis…
of
bus… 5,0… —
and
ass…
net
Tra… -671 -6,…
cos…
Sig…
lit…
mat… -298 -12…
and
set…
Sig…
env… — 1,2…
mat…
Res…
and -74… -24…
oth…
Rep…
ope…
inc… $ 260… $ 244…
from
con…
ope…
REV…
AND
REP…
OPE…
INC…
(LO…
PRE…
IN
ACC…
WITH
GAAP
Revvity, Inc. and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS
October 4, December 28,
(In thousands) 2026 2025
──────────────────────────────────────────────────────────────────────────────
Current assets:
Cash and cash equivalents $ 592,799 $ 919,860
Accounts receivable, net 687,328 744,671
Inventories, net 388,850 379,497
Other current assets 192,414 195,719
Total current assets 1,861,391 2,239,747
Property, plant and 450,870 479,249
equipment, net
Operating lease 146,823 165,439
right-of-use assets, net
Intangible assets, net 2,137,551 2,347,003
Goodwill 6,588,150 6,613,493
Other assets, net 305,561 323,480
Total assets $ 11,490,346 $ 12,168,411
Current liabilities:
Current portion of $ — $ 588,828
long-term debt
Accounts payable 163,271 185,464
Accrued expenses and other
current 538,206 556,954
liabilities
Total current liabilities 701,477 1,331,246
Long-term debt 2,634,062 2,631,236
Long-term liabilities 752,731 807,461
Operating lease 130,970 148,108
liabilities
Total liabilities 4,219,240 4,918,051
Total stockholders' equity 7,271,106 7,250,360
Total liabilities and
stockholders' $ 11,490,346 $ 12,168,411
equity
PREPARED IN ACCORDANCE
WITH GAAP
Revvity, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
Three October Septe… Nine Octob… Septem…
(In Months 4, 28, Months 4, 28,
thous… Ended 2026 2025 Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Oper…
acti…
Net $ 62,299 $ 46,652 $ 154,8… $ 142,837
inco…
Loss
from
disc…
oper… 322 569 2,158 1,275
net
of
inco…
taxes
Inco…
from 62,621 47,221 156,9… 144,112
cont…
oper…
Adju…
to
reco…
inco…
from
cont…
oper…
to
net
cash
prov…
by
cont…
oper…
Stoc… 9,752 9,054 29,198 26,918
comp…
Rest…
and 28,357 9,926 74,540 24,368
other
Depr…
and 102,918 102,0… 310,0… 302,261
amor…
Chan…
in
fair
value 60 107 1,587 -59
of
cont…
cons…
Amor…
of
defe…
debt
fina… 1,007 1,240 3,447 3,560
costs
and
accr…
of
disc…
Chan…
in
fair -1,627 4,602 7,828 3,484
value
of
inve…
Unre…
fore… — 82 186 222
exch…
loss
Gains
on
disp…
of — — -5,074 —
busi…
and
asse…
net
Chan…
in
asse…
and
liab…
which
(use…
prov…
cash:
Acco…
rece… 22,489 -19,7… 66,405 -41,643
net
Inve… -13,354 6,851 -18,1… 12,493
net
Acco… -1,585 -3,008 -19,6… 270
paya…
Accr…
expe… -43,934 -19,8… -122,… -68,990
and
other
Net
cash
prov…
by
oper… 166,704 138,5… 484,5… 406,996
acti…
of
cont…
oper…
Net
cash
used
in
oper… — -81 -10,6… -6,023
acti…
of
disc…
oper…
Net
cash
prov… 166,704 138,5… 473,8… 400,973
by
oper…
acti…
Inve…
acti…
Capi… -14,346 -18,5… -45,1… -53,351
expe…
Purc…
of
inve… -1,250 -29 -4,811 -29
and
notes
rece…
Proc…
from
inve… — — 7,496 —
and
notes
rece…
Proc…
from
disp…
of — — 12,039 —
prop…
plant
and
equi…
Proc…
from
disp…
of — — 158 229
busi…
and
asse…
Cash
paid
for
acqu… — — -67,0… —
net
of
cash
acqu…
Net
cash
used
in
inve… -15,596 -18,5… -97,3… -53,151
acti…
of
cont…
oper…
Net
cash
prov…
by
inve… — 37,500 — 56,250
acti…
of
disc…
oper…
Net
cash
(used
in) -15,596 18,970 -97,3… 3,099
prov…
by
inve…
acti…
Three Nine
Months Months
Ended Ended
Octob… Septe… Octob… Septe…
(In 4, 28, 4, 28,
thou… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Fina…
Acti…
Paym…
on $ -25,0… $ — $ -25,0… $ —
borr…
Proc…
from 25,000 — 25,000 —
borr…
Paym…
of
seni… -571,… — -571,… —
unse…
notes
Paym…
of
debt — — — -2,4…
fina…
costs
Paym…
on
other — -55 — -158
cred…
faci…
Paym…
for
acqu… — -1,860 -350 -3,8…
cont…
cons…
Proc…
from
issu…
of
comm… 3,485 — 9,922 2,632
stock
under
stock
plans
Purc…
of -95 -205,… -102,… -652…
comm…
stock
Divi… -7,811 -8,130 -23,4… -24,…
paid
Net
cash
used -575,… -215,… -687,… -681…
in
fina…
acti…
Effe…
of
exch…
rate
chan…
on -5,709 -2,811 -15,8… 45,2…
cash,
cash
equi…
and
rest…
cash
Net
decr…
in
cash,
cash -430,… -60,4… -327,… -231…
equi…
and
rest…
cash
Cash,
cash
equi…
and
rest… 1,024… 992,9… 921,0… 1,16…
cash
at
begi…
of
peri…
Cash,
cash
equi…
and
rest… $ 593,9… $ 932,5… $ 593,9… $ 932,…
cash
at
end
of
peri…
Supp…
disc…
of
cash
flow
info…
Reco…
of
cash,
cash
equi…
and
rest…
cash
repo…
with…
the
cond…
cons…
bala…
shee…
that
sum
to
the
total
shown
in
the
cons…
stat…
of
cash
flow…
Cash
and $ 592,7… $ 931,3… $ 592,7… $ 931,…
cash
equi…
Rest…
cash
incl…
in 600 1,189 600 1,189
other
curr…
asse…
Rest…
cash
incl… 567 — 567 —
in
other
asse…
Total
cash,
cash
equi… $ 593,9… $ 932,5… $ 593,9… $ 932,…
and
rest…
cash
PREP…
IN
ACCO…
WITH
GAAP
Revvity, Inc. and Subsidiaries
RECONCILIATI
ON OF FINANCIAL METRICS
(1)
Continuing Operations
Three Months Ended
October 4, 2026
───────────────────────────────────────────────────────────────────────────
Pro forma organic revenue growth:
Pro forma revenue growth from continuing 7%
operations
Less: effect of foreign exchange rates -1%
Less: effect of acquisitions including purchase
accounting adjustments and impact of divested 1%
businesses
Pro forma organic revenue growth from continuing 7%
operations
Life Sciences
Three Months Ended
October 4, 2026
Pro forma organic revenue growth:
Pro forma revenue growth from continuing 11%
operations
Less: effect of foreign exchange rates 0%
Less: effect of acquisitions including purchase
accounting adjustments and impact of divested 2%
businesses
Pro forma organic revenue growth from continuing 9%
operations
Diagnostics
Three Months Ended
October 4, 2026
Pro forma organic revenue growth:
Pro forma revenue growth from continuing 4%
operations
Less: effect of foreign exchange rates -1%
Less: effect of acquisitions including purchase
accounting adjustments and impact of divested 0%
businesses
Pro forma organic revenue growth from continuing 5%
operations
(1) amounts may not sum due to rounding
Revvity, Inc. and Subsidiaries
RECONCILIATI
ON OF FINANCIAL METRICS
(1)
Continuing Operations
Nine Months Ended
October 4, 2026
───────────────────────────────────────────────────────────────────────────
Pro forma organic revenue growth:
Pro forma revenue growth from continuing 7%
operations
Less: effect of foreign exchange rates 1%
Less: effect of acquisitions including purchase
accounting adjustments and impact of divested 1%
businesses
Pro forma organic revenue growth from continuing 5%
operations
Life Sciences
Nine Months Ended
October 4, 2026
Pro forma organic revenue growth:
Pro forma revenue growth from continuing 5%
operations
Less: effect of foreign exchange rates 1%
Less: effect of acquisitions including purchase
accounting adjustments and impact of divested 1%
businesses
Pro forma organic revenue growth from continuing 3%
operations
Diagnostics
Nine Months Ended
October 4, 2026
Pro forma organic revenue growth:
Pro forma revenue growth from continuing 9%
operations
Less: effect of foreign exchange rates 1%
Less: effect of acquisitions including purchase
accounting adjustments and impact of divested 0%
businesses
Pro forma organic revenue growth from continuing 8%
operations
(1) amounts may not sum due to rounding
Explanation of Non-GAAP Financial Measures
We report our financial results in accordance with GAAP. However, management
believes that, in order to more fully understand our short-term and long-term
financial and operational trends, investors may wish to consider the impact of
certain non-cash, non-recurring or other items, which result from facts and
circumstances that vary in frequency and impact on continuing operations.
Accordingly, we present non-GAAP financial measures as a supplement to the
financial measures we present in accordance with GAAP. These non-GAAP financial
measures provide management with additional means to understand and evaluate the
operating results and trends in our ongoing business by adjusting for certain
non-cash expenses and other items that management believes might otherwise make
comparisons of our ongoing business with prior periods more difficult, obscure
trends in ongoing operations, or reduce management’s ability to make useful
forecasts. Management believes these non-GAAP financial measures provide
additional means of evaluating period-over-period operating performance. In
addition, management understands that some investors and financial analysts find
this information helpful in analyzing our financial and operational performance
and comparing this performance to our peers and competitors.
We use the term “organic revenue” to refer to GAAP revenue, excluding the effect
of foreign currency changes and revenue from recent acquisitions, divestitures
and including purchase accounting adjustments for revenue from contracts
acquired in acquisitions that will not be fully recognized due to accounting
rules. We use the related term “organic revenue growth” or “organic growth” to
refer to the measure of comparing current period organic revenue with the
corresponding period of the prior year.
We use the term “adjusted gross margin” to refer to GAAP gross margin, excluding
amortization of intangible assets and inventory fair value adjustments related
to business acquisitions and asset impairments. We use the related term
“adjusted gross margin percentage” to refer to adjusted gross margin as a
percentage of revenue.
We use the term “adjusted SG&A expense” to refer to GAAP SG&A expense, excluding
amortization of intangible assets, purchase accounting adjustments, acquisition
and divestiture-related expenses, transformation costs, significant litigation
matters and settlements, asset impairments, significant environmental charges,
and restructuring and other charges. We use the related term “adjusted SG&A
percentage” to refer to adjusted SG&A expense as a percentage of revenue.
We use the term “adjusted R&D expense” to refer to GAAP R&D expense, excluding
amortization of intangible assets and purchase accounting adjustments. We use
the related term “adjusted R&D percentage” to refer to adjusted R&D expense as a
percentage of revenue.
We use the term “adjusted net interest and other expense” to refer to GAAP net
interest and other expense, excluding adjustments for mark-to-market accounting
on post-retirement benefits, changes in foreign exchange and interest associated
with acquisitions and divestitures, changes in the value of investments and debt
extinguishment costs.
We use the term “adjusted operating income” to refer to GAAP operating income,
excluding amortization of intangible assets, purchase accounting adjustments,
acquisition and divestiture-related expenses, transformation costs, significant
litigation matters and settlements, significant environmental charges, asset
impairments, and restructuring and other charges. We use the related terms
“adjusted operating profit percentage,” “adjusted operating profit margin,” and
“adjusted operating margin” to refer to adjusted operating income as a
percentage of revenue.
We use the term “free cash flow” to refer to net cash provided by (used in)
operating activities of continuing operations, less payments for additions to
property, plant and equipment from continuing operations (“capital
expenditures”) plus the proceeds from sales of plant, property and equipment
from continuing operations (“capital disposals”).
We use the term “adjusted net income” to refer to GAAP income from continuing
operations, excluding amortization of intangible assets, debt extinguishment
costs, purchase accounting adjustments, acquisition and divestiture-related
expenses, transformation costs, significant litigation matters and settlements,
significant environmental charges, changes in the value of investments,
disposition of businesses and assets, net, changes in foreign exchange and
interest associated with acquisitions and divestitures, asset impairments and
restructuring and other charges. We also exclude adjustments for mark-to-market
accounting on post-retirement benefits, therefore only our projected costs have
been used to calculate this non-GAAP measure. We also adjust for any tax impact
related to the above items and exclude the impact of significant tax events.
We use the term “adjusted earnings per share from continuing operations,”
“adjusted earnings per share,” “adjusted EPS,” or “adjusted EPS from continuing
operations” to refer to GAAP earnings per share from continuing operations,
excluding amortization of intangible assets, debt extinguishment costs, purchase
accounting adjustments, acquisition and divestiture-related expenses,
transformation costs, significant litigation matters and settlements,
significant environmental charges, changes in the value of investments,
disposition of businesses and assets, net, changes in foreign exchange and
interest associated with acquisitions and divestitures, asset impairments and
restructuring and other charges. We also exclude adjustments for mark-to market
accounting on post-retirement benefits, therefore only our projected costs have
been used to calculate this non-GAAP measure. We also adjust for any tax impact
related to the above items and exclude the impact of significant tax events.
We use the term “pro forma organic revenue” to refer to organic revenue
excluding revenue from probable dispositions. We use the related term “pro forma
organic revenue growth”, “pro forma organic revenue growth from continuing
operations” or “pro forma organic growth” to refer to the measure of comparing
current period pro forma organic revenue with the corresponding period of the
prior year.
We use the term “pro forma adjusted gross margin” to refer to adjusted gross
margin, excluding gross margin from probable dispositions. We use the related
term “pro forma adjusted gross margin percentage” to refer to pro forma adjusted
gross margin as a percentage of pro forma revenue.
We use the term “pro forma adjusted SG&A expense” to refer to adjusted SG&A
expense, excluding SG&A expense from probable dispositions and gains(losses) on
sale of probable dispositions. We use the related term “pro forma adjusted SG&A
percentage” to refer to pro forma adjusted SG&A expense as a percentage of pro
forma revenue.
We use the term “pro forma adjusted R&D expense” to refer to adjusted R&D
expense, excluding R&D expense from probable dispositions. We use the related
term “pro forma adjusted R&D percentage” to refer to pro forma adjusted R&D
expense as a percentage of pro forma revenue.
We use the term “pro forma adjusted net interest and other expense” to refer to
adjusted net interest and other expense, excluding net interest and expense from
probable dispositions.
We use the term “pro forma adjusted operating income” to refer to adjusted
operating income, excluding operating income from probable dispositions. We use
the related terms “pro forma adjusted operating profit percentage,” “pro forma
adjusted operating profit margin,” and “pro forma adjusted operating margin” to
refer to pro forma adjusted operating income as a percentage of pro forma
revenue.
We use the term “pro forma adjusted earnings per share from continuing
operations,” “pro forma adjusted earnings per share,” “pro forma adjusted EPS,”
or “pro forma adjusted EPS from continuing operations” to refer to adjusted
earnings per share from continuing operations, excluding net income from
probable dispositions and gains (losses) on sale of probable dispositions.
Management includes or excludes the effect of each of the items identified below
in the applicable non-GAAP financial measure referenced above for the reasons
set forth below with respect to that item:
• Amortization of intangible assets —purchased intangible assets are amortized
over their estimated useful lives and generally cannot be changed or influenced
by management after the acquisition. Accordingly, this item is not considered by
management in making operating decisions. Management does not believe such
charges accurately reflect the performance of our ongoing operations for the
period in which such charges are incurred.
• Debt extinguishment costs —we incur costs and income related to the
extinguishment of debt, including make-whole payments to debt holders,
accelerated amortization of debt fees and discounts, and expense or income from
hedges to lock in make-whole payments. We exclude the impact of these items from
our non-GAAP measures because we believe they do not reflect the performance of
our ongoing operations.
• Purchase accounting adjustments —accounting rules require us to adjust various
balance sheet accounts, including inventory, fixed assets, deferred revenue and
deferred rent balances to fair value at the time of the acquisition. As a
result, the expenses for these items in our GAAP results are not the same as
what would have been recorded by the acquired entity. Accounting rules also
require us to estimate the fair value of contingent consideration at the time of
the acquisition, and any subsequent changes to the estimate or payment of the
contingent consideration and purchase accounting adjustments are charged to
expense or income. We exclude the impact of any changes to contingent
consideration from our non-GAAP measures because we believe these expenses or
benefits do not accurately reflect the performance of our ongoing operations for
the period in which such expenses or benefits are recorded.
• Acquisition and divestiture-related expenses —we incur legal, due diligence,
stay bonuses, incentive awards, stock-based compensation, interest, foreign
exchange gains and losses, integration expenses, rebranding expenses, and other
costs related to acquisitions and divestitures. We exclude these expenses from
our non-GAAP measures because we believe they do not reflect the performance of
our ongoing operations.
• Transformation costs —transformation costs consist of external professional
service costs related to transformation initiatives focused on business
processes modernization, automation, and implementation of global systems to
support the new Revvity Business Model. T hese costs are determined to be
noncapitalizable in accordance with accounting standards. Management does not
believe such costs accurately reflect the performance of our ongoing operations
for the period in which such costs are reported.
• Asset impairments —we incur expenses related to asset impairments. Management
does not believe such charges accurately reflect the performance of our ongoing
operations for the periods in which such charges were incurred.
• Restructuring and other charges —restructuring and other charges consist of
employee severance, other exit costs, abandonments or associated asset write-
downs, cost of terminating certain lease agreements or contracts as well as
costs associated with relocating facilities. Management does not believe such
costs accurately reflect the performance of our ongoing operations for the
period in which such costs are reported.
• Adjustments for mark-to-market accounting on post-retirement benefits —we
exclude adjustments for mark-to-market accounting on post-retirement benefits,
and therefore only our projected costs are used to calculate our non-GAAP
measures. We exclude these adjustments because they do not represent what we
believe our investors consider to be costs of producing our products,
investments in technology and production, and costs to support our internal
operating structure.
• Significant litigation matters and settlements —we incur expenses related to
significant litigation matters, including the costs to settle or resolve various
claims and legal proceedings. Management does not believe such charges
accurately reflect the performance of our ongoing operations for the periods in
which such charges were incurred.
• Significant environmental charges —we incur expenses related to significant
environmental charges. Management does not believe such charges accurately
reflect the performance of our ongoing operations for the periods in which such
charges were incurred.
• Disposition of businesses and assets, net —we exclude the impact of gains or
losses from the disposition of businesses and assets from our adjusted earnings
per share. Management does not believe such gains or losses accurately reflect
the performance of our ongoing operations for the period in which such gains or
losses are reported.
• Impact of foreign currency changes on the current period —we exclude the
impact of foreign currency associated with acquisitions and divestitures from
these measures by using the prior period’s foreign currency exchange rates for
the current period because foreign currency exchange rates are subject to
volatility and can obscure underlying trends.
• Impact of significant tax events —we exclude the impact of significant tax
events. Management does not believe the impact of significant tax events
accurately reflects the performance of our ongoing operations for the periods in
which the impact of such events was recorded.
• Change in fair value of investments —we exclude the impact of changes in the
value of investments. Management does not believe such gains or losses
accurately reflect the performance of our ongoing operations for the period in
which such gains or losses are reported.
# # #
The tax effect for discontinued operations is calculated based on the
authoritative guidance in the Financial Accounting Standards Board’s Accounting
Standards Codification 740, Income Taxes. The tax effect for amortization of
intangible assets, inventory fair value adjustments related to business
acquisitions, changes to the fair values assigned to contingent consideration,
debt extinguishment costs, other costs related to business acquisitions and
divestitures, transformation costs, loss from probable dispositions, significant
litigation matters and settlements, significant environmental charges, changes
in the fair value of investments, adjustments for mark-to-market accounting on
post-retirement benefits, disposition of businesses and assets, net, and
restructuring and other charges is calculated based on operational results and a
blended jurisdictional tax rate, which contemplates tax rates currently in
effect to determine our tax provision. The tax effect for the impact from
foreign currency exchange rates on the current period is calculated based on a
blended jurisdictional tax rate currently in effect to determine our tax
provision.
The non-GAAP financial measures described above are not meant to be considered
superior to, or a substitute for, our financial statements prepared in
accordance with GAAP. There are material limitations associated with non-GAAP
financial measures because they exclude charges that have an effect on our
reported results and, therefore, should not be relied upon as the sole financial
measures by which to evaluate our financial results. Management compensates and
believes that investors should compensate for these limitations by viewing the
non-GAAP financial measures in conjunction with the GAAP financial measures. In
addition, the non-GAAP financial measures included in this earnings announcement
may be different from, and therefore may not be comparable to, similar measures
used by other companies.
Each of the non-GAAP financial measures listed above is also used by our
management to evaluate our operating performance, communicate our financial
results to our Board of Directors, benchmark our results against our historical
performance and the performance of our peers, evaluate investment opportunities
including acquisitions and discontinued operations, and determine the bonus
payments for senior management and employees.
Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com
Media Relations:
Chet Murray
(781) 462-5126
chet.murray@revvity.com